



16. Pyrazole compounds of formula (Ia) or (Ib) according to any of the preceding claims, wherein R^3 if present are independently selected from halogen.

17. Pyrazole compounds of formula (Ia) according to any of the preceding claims,
5 wherein the pyrazole compounds are selected from compounds of formula (Ia'),



wherein Z, R^1 , R^2 , R^3 , R^{Y1} , R^{Y2} , R^{Y3} , R^{Y4} and R^{Y5} have one of the meanings given in any of the preceding claims and n is 0 or 1.


10 18. Pyrazole compounds of formula (Ib) according to any of claims 1 to 16, wherein the pyrazole compounds are selected from compounds of general formula (Ib'),



wherein Z, R^1 , R^2 , R^3 , R^{Y1} , R^{Y2} , R^{Y3} , R^{Y4} and R^{Y5} have one of the meanings given in any of the preceding claims and n is 0 or 1.


15

19. A pyrazole compound of formula (Compound 4) and pharmaceutically acceptable salts thereof,






(Compound 4).



20. A pyrazole compound of formula (1a) or (1b) and pharmaceutically acceptable salts thereof, selected from the group consisting of:






5






10
























5











10



























5




10











(Compound 57);



(Compound 58); and



(Compound 59).

5

21. Pyrazole compounds of formula (Ia) or (Ib) according to any of the preceding claims for use as medicaments.

10 22. Pyrazole compounds of formula (Ia) or (Ib) according to any of claims 1 to 20 for use for the prevention and/or treatment of inflammatory,

infectious and immunoregulatory disorders, respiratory or gastrointestinal diseases or complaints, inflammatory diseases of the joints and allergic diseases of the nasopharynx, eyes, and skin.

23. Use of pyrazole compounds of formula (Ia) or (Ib) according to any of claims 1 to 20 in the manufacture of a medicament for the prevention and/or treatment of inflammatory, infectious and immunoregulatory disorders, respiratory or gastrointestinal diseases or complaints, inflammatory diseases of the joints and allergic diseases of the nasopharynx, eyes, and skin such as rheumatoid arthritis, atherosclerosis, allergic or non-allergic rhinitis or sinusitis, chronic sinusitis or rhinitis, nasal polyposis, chronic rhinosinusitis, acute rhinosinusitis, asthma, pediatric asthma, allergic bronchitis, alveolitis, Farmer's disease, hyperreactive airways, allergic conjunctivitis, bronchitis or pneumonitis caused by infection, e.g. by bacteria or viruses or helminthes or fungi or protozoans or other pathogens, bronchiectasis, adult respiratory distress syndrome, bronchial and pulmonary edema, bronchitis or pneumonitis or interstitial pneumonitis caused by different origins, e.g. aspiration, inhalation of toxic gases, vapors, bronchitis or pneumonitis or interstitial pneumonitis caused by heart failure, X-rays, radiation, chemotherapy, bronchitis or pneumonitis or interstitial pneumonitis associated with collagenosis, e.g. lupus erythematosus, systemic scleroderma, lung fibrosis, idiopathic pulmonary lung fibrosis (IPF), interstitial lung diseases or interstitial pneumonitis of different origin, including asbestosis, silicosis, m. Boeck or sarcoidosis, granulomatosis, cystic fibrosis or mucoviscidosis, or α 1-antitrypsin deficiency, eosinophilic cellulites (e.g., Wells' syndrome), eosinophilic pneumonias (e.g., Loeffler's syndrome, chronic eosinophilic pneumonia), eosinophilic fasciitis (e.g., Shulman's syndrome), delayed-type hypersensitivity, non-allergic asthma; exercise induced bronchoconstriction; chronic obstructive pulmonary disease (COPD), acute bronchitis, chronic bronchitis, cough, pulmonary emphysema; systemic anaphylaxis or hypersensitivity responses, drug allergies (e.g., to penicillin, cephalosporin), eosinophilia-myalgia syndrome due to the ingestion of contaminated tryptophan, insect sting allergies; autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, immune thrombocytopenia (adult ITP, neonatal thrombocytopenia, pediatric ITP), immune hemolytic anemia (auto-immune and drug induced), Evans syndrome (platelet and red cell immune cytopaenias), Rh disease of the newborn, Goodpasture's syndrome (anti-GBM disease), Celiac, autoimmune cardio-myopathy juvenile onset diabetes; glomerulonephritis, autoimmune thyroiditis, Behcet's disease; graft rejection (e.g., in transplantation), including allograft rejection

or graft-versus-host disease; inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis; spondyloarthropathies; scleroderma; psoriasis (including T-cell mediated psoriasis) and inflammatory dermatoses such as an dermatitis, eczema, atopic dermatitis, allergic contact dermatitis, urticaria; vasculitis (e. g., necrotizing, cutaneous, and hypersensitivity vasculitis); erythema nodosum; eosinophilic myositis, eosinophilic fasciitis, cancers with leukocyte infiltration of the skin or organs.

24. Pharmaceutical formulations, containing one or more of the pyrazole compound of formula (Ia) and/or (Ib) according to any of claims 1 to 20.

25. Pharmaceutical formulations, containing one or more pyrazole compound of formula (Ia) and/or (Ib) according to any of claims 1 to 20 in combination with one or more active substances selected from among betamimetics, anticholinergics, corticosteroids, PDE4 inhibitors, LTD4 antagonists, EGFR inhibitors, CCR3 antagonists, CCR5 antagonists, CCR9 antagonists, 5-LO inhibitors, histamine-receptor antagonists, SYK inhibitors and sulfonamides.